医学
抗逆转录病毒疗法
重症监护医学
人类免疫缺陷病毒(HIV)
药理学
免疫学
病毒载量
作者
Analuz Fernández,Arkaitz Imaz
标识
DOI:10.1080/17512433.2024.2365826
摘要
New ARV drugs offer advantages in efficacy and safety over previous options but may also have adverse effects. Second-generation integrase inhibitors and tenofovir alafenamide show benefits as switching options in various scenarios, though more research is needed on potential weight gain and metabolic issues. Injectable long-acting ART is promising for switching strategies, but finding the optimal combination of new drugs remains challenging.
科研通智能强力驱动
Strongly Powered by AbleSci AI